[Abstract Only] Observational Study: SGLT-2 Inhibitors Linked to Lower Risk of Gout vs. GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary: SGLT-2 inhibitors associated with lower risk of gout vs. GLP-1 receptor agonists – ACP Hospitalist (free)